March 2015 Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times. This equipment will form part of the manufacturing process for clinical […]
November 2014 Oval Medical received £25,000 to contribute to market research for its new, innovative epinephrine autoinjector for the treatment of anaphylactic shock. The incidence of allergies that can cause this serious and potentially fatal reaction is growing worldwide. Oval’s epinephrine autoinjector incorporates the same design philosophy as the first device being used for sumatriptan. […]
Press Release For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together in […]
Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]
Drug development pipelines are tending towards increasing numbers of injectable products, and amongst these an ever larger proportion are viscous biologics and sustained-release formulations.
Inclusive design has unique challenges because it aims to improve usability for a wide range of users. This typically includes people with lower levels of ability, as well as mainstream users. This paper examines the effectiveness of two methods that are used in inclusive design.
Oval Medical Technologies Ltd (‘Oval’) today announced that they have signed another deal following an initial feasibility study with a global pharmaceutical company, to a value in excess of one million pounds. The feasibility study, which primarily focused on the pharmaceutical drug’s stability in Oval’s standard primary drug container, started in March 2012 and completed […]
The board of Oval Medical Technologies Limited (‘Oval’) announces that effective from 1st May 2013, Barbara Lead has succeeded Dr Catherine Beech as Chief Executive Officer of Oval Medical Technologies Limited. Catherine was instrumental in establishing Oval with Matthew Young in late 2009 and completing the initial Angel financing in early 2010. Since then, with […]
30th May 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that functional prototypes of their autoinjector technology are now available. Oval’s specification for a standard 1ml device was clearly met by delivering 1ml of drug subcutaneously, through a 27G needle in less than 7 seconds. The fully functional injection-moulded prototypes demonstrate the simplicity […]
17th April 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that a variety of 1100 cPs solutions (the thickness of motor oil) have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector. Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector […]